3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
104
Multiple Myeloma
66
Lymphoma
60
Precursor Cell Lymphoblastic Leukemia-Lymphoma
57
Myelodysplastic Syndromes
51
Lymphoma, Non-Hodgkin
51
Leukemia
50
Hodgkin Disease
42
Lymphoma, Mantle-Cell
29
Lymphoma, Large B-Cell, Diffuse
29
Leukemia, Lymphocytic, Chronic, B-Cell
26
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
23
Lymphoma, Follicular
22
Burkitt Lymphoma
22
Breast Neoplasms
22
Recurrence
20
Neoplasms, Plasma Cell
18
Neuroblastoma
17
Hematologic Neoplasms
17
Lymphoma, B-Cell, Marginal Zone
15
Myeloproliferative Disorders
14
Lymphoma, Large-Cell, Immunoblastic
14
Leukemia, Myelomonocytic, Chronic
12
Leukemia, Biphenotypic, Acute
12
Congenital Abnormalities
12
Blast Crisis
10
Anemia, Refractory, with Excess of Blasts
10
Retinoblastoma
9
Central Nervous System Neoplasms
9
Sarcoma
8
Interventions
Dexamethasone
7
Lenalidomide
5
isatuximab
3
fludarabine
3
daratumumab
3
Cyclophosphamide
3
Bortezomib
3
pomalidomide
2
Tacrolimus
2
Alemtuzumab
2
plerixafor
1
ofatumumab
1
nirogacestat
1
fludarabine phosphate
1
Whole-Body Irradiation
1
Tissue Banks
1
Thalidomide
1
Stem Cell Transplantation
1
Rifaximin
1
Ranitidine
1
Mycophenolic Acid
1
Melphalan
1
Granulocyte Colony-Stimulating Factor
1
Etoposide
1
Doxorubicin
1
Diphenhydramine
1
Clonal Hematopoiesis
1
Cisplatin
1
Chromatin Immunoprecipitation Sequencing
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Paraproteinemias
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT01186224
2025-03-17
PHANTASTIC
University of Liverpool
Phase NA
Completed
60 enrolled